New hope for rare kidney cancers: drug duo shows promise in early trial
Disease control
Ongoing
This study tests a combination of two drugs, cadonilimab and axitinib, as a first treatment for people with advanced or spreading kidney cancer that has a rare cell type. The goal is to see if the combo is safe and shrinks tumors. About 37 adults will take the drugs until their d…
Phase: PHASE1, PHASE2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated May 04, 2026 16:25 UTC